Motloch, LJ;,
Jirak, P;,
Gareeva, D;,
Davtyan, P;,
Gumerov, R;,
Lakman, I;,
Tataurov, A;,
Zulkarneev, R;,
Kabirov, I;,
Cai, BZ;,
Valeev, B;,
Pavlov, V;,
Kopp, K;,
Hoppe, UC;,
Lichtenauer, M;,
Fiedler, L;,
Pistulli, R;,
Zagidullin, N (2022) -cause mortality at 1 year
follow-up [FU: 354 days (342; 361)].
Results: 11 patients died while hospitalized
Johnson, N.,
Maguire, S.,
Morra, A.,
Kapoor, P.M.,
Tomczyk, K.,
Jones, M.E.,
Schoemaker, M.J.,
Gilham, C.,
Bolla, M.K.,
Wang, Q.,
Bermisheva, M. (2021) with breast cancer risk, we carried out
follow-up genotyping in 90,916 cases and 89,893 controls from
Bikbov, Mukharram M.,
Kazakbaeva, Gyulli M.,
Rakhimova, Ellina M.,
Panda-Jonas, Songhomitra,
Tuliakova, Azaliia M.,
Fakhretdinova, Albina A.,
Jonas, Jost B. (2025) : In the UEMS, 689 (11.7%) participants had died during the
follow-up of 7.0 ± 0.4 years (median: 6.9 years
Bikbov, Mukharram M.,
Kazakbaeva, Gyulli M.,
Holz, Frank G.,
Panda-Jonas, Songhomitra,
Gilemzianova, Leisan I.,
Khakimov, Dinar A.,
Jonas, Jost B. (2023) (13.8±2.4 mm Hg vs 14.3±2.6 mm Hg; p=0.20) remained unchanged. In nine patients with a
follow-up of >3
Chu, Shuk Han,
Zhao, Xu,
Komber, Ahmad,
Cheyne, Joshua,
Wu, Simiao,
Cowey, Eileen,
Kutlubaev, Mansur,
Mead, Gillian (2023) .31; I2 = 86%, p < 0.00001), but not at
follow-up (265 participants, pooled SMD = −0.14, 95% CI: −0